Table 1 Demographic, disease-specific, and DXA characteristics of rheumatic patients scheduled for THA and TKA

 Females (%)

11/25 (44%)

18/25 (72%)

0.045*^#

 Age (yr.)

71.0 (10.8)

63.2 (14.2)

0.035*

 Height (cm)

170.2 (8.2)

166.6 (10.6)

0.093

 Weight (kg)

77.4 (13.4)

78.1 (16.2)

0.861

 BMI (kg/m²)

26.6 (3.6)

28.5 (5.4)

0.150

 Smoking (%)

4/25 (16%)

4/25 (16%)

1.0^#

 RA

21/25 (84%)

21/25 (84%)

1.000^#

 PsA

1/25 (4%)

3/25 (12%)

0.297^#

 AS

3/25 (12%)

1/25 (4%)

0.297^#

 Glucocorticoids

12/25 (48%)

17/25 (68%)

0.152

 Glucocorticoid dose (mg)

5.3 (2.7)

5.4 (3.3)

0.937

 MTX (%)

12/25 (48%)

17/25 (68%)

0.152^#

 MTX dose (mg)

14.2 (2.9)

14.7 (4.0)

0.719

 Biologicals (%)

6/25 (24%)

4/25 (16%)

0.480^#

 Kellgren-Lawrence Score

3.1 (0.73)

3.1 (0.64)

0.837

 Cemented femoral component fixation

11/25 (44%)

14/25 (56%)

0.396^#

 T-score – femur lowest

−1.0 (1.3)

−1.7 (1.2)

0.067

 Z-score – femur lowest

0.0 (1.2)

−0.9 (1.2)

0.010^*

 T-score – affected femur

−0.8 (1.3)

−1.4 (1.3)

0.114

 Z-score – affected femur

0.2 (1.2)

−0.7 (1.2)

0.013^*

 T-score – contralateral femur

−0.8 (1.1)

−1.4 (1.2)

0.136

 Z-score – contralateral femur

0.3 (0.9)

−0.6 (1.2)

0.012^*

 T-score – lumbar spine

−0.5 (2.1)

−1.1 (1.8)

0.333

 Z-score – lumbar spine

0.4 (1.8)

−0.4 (2.2)

0.180

 Osteoporosis (T-score ≤ −2.5)

3/25 (12%)

8/25 (32%)

0.088^#

 Osteopenia (T-score ≤ −1 - ≤ −2.5)

13/25 (52%)

13/25 (52%)

1.000^#

 Vitamin D supplementation

6/25 (24%)

7/25 (26%)

0.747^#

 Bone-specific treatment

1/25 (4%)

2/25 (8%)

0.552^#

 Indication bone-specific treatment

10/25 (40%)

11/25 (44%)

0.774^#